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ABSTRACT
Stenotrophomonas maltophilia has emerged as an important opportunistic pathogen in 
the last decade. Increased resistance to sulfamethoxazole/trimethoprim (SMX/TMP) has been 
reported in S. maltophilia strains in the past few years, leading to few therapeutic options. We 
conducted a prospective multicenter study at two Brazilian teaching hospitals that identified 
S. maltophilia isolates and evaluated their antimicrobial susceptibility profile, SMX/TMP 
resistance genes and their clonality profile. A total of 106 non-repeated clinical samples 
of S. maltophilia were evaluated. Resistance to SMX/TMP was identified in 21.6% of the 
samples, and previous use of SMX/TMP occurred in 19 (82.6%). PCR detected the sul1 gene 
in 14 of 106 strains (13.2%). Of these isolates, nine displayed resistance to SMX/TMP. The 
resistant strains presented a polyclonal profile. This opportunistic pathogen has emerged in 
immunocompromised hosts, with few therapeutic options, which is aggravated by the description 
of emerging resistance mechanisms, although with a polyclonal distribution profile.
KEYWORDS: Stenotrophomonas maltophilia. Immunocompromised patients. 
Sulfamethoxazole/trimethoprim resistance. Gram-negative infection.
INTRODUCTION
The management of Stenotrophomonas maltophilia infection is usually 
challenging as a result of its intrinsic resistance profile to the various classes of 
antimicrobials1. S. maltophilia produces chromosomal β-lactamases (L1 and L2), 
which presents an impermeable membrane that expresses efflux pumps and acquires 
additional resistance genes in class 1 integrons2. To date, the treatment of choice for 
infections caused by S. maltophilia has been sulfamethoxazole/trimethoprim (SMX/
TMP)3. However, resistance to this drug has increased in recent years, mainly due 
to the spread of sul-1, sul-2, and dfrA genes4.
The aim of this study was to describe the clinical and microbiological 
characteristics of S. maltophilia isolates and to study its antimicrobial susceptibility, 
presence of resistance genes and clonality profile.
MATERIALS AND METHODS
Study design
A prospective multicenter study was conducted over a 2-year period 
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(January 2009 to December 2010) in two Brazilian teaching 
hospitals: Hospital das Clinicas, Faculty of Medicine, Sao 
Paulo University (2,000 beds) and an oncology center at 
Hospital A.C. Camargo (450 beds). We collected clinical 
samples and evaluated demographic and clinical data of 
patients colonized or infected by S. maltophilia. Patients 
were classified as colonized by S. maltophilia if the isolates 
were identified from the tip of a central venous catheter 
(CVC) and/or CVC blood samples and infected based on 
the Centers for Diseases Control and Prevention (CDC) 
criteria5. The following variables were evaluated: sex, age, 
hospital unit (nursery, intensive care unit, transplantation 
unit etc.), underlying diseases, presence of CVC, site 
of colonization or infection, previous use of SMX/TMP 
and drug used to treat the S. maltophilia infection. A 
database was created using Epi Info software version 3.5.1 
(Centers for Disease Control and Prevention, Atlanta, 
USA). Variables were evaluated as frequencies, means 
and medians.
Microbiology
Isolates were identified by API 20 NE (bioMérieux, 
Craponne, France). The microdilution method was used 
to evaluate susceptibility to SMX/TMP, ciprofloxacin, 
levofloxacin, minocycline, ceftazidime, chloramphenicol 
and ticarcillin/clavulanate according to the Clinical 
& Laboratory Standards Institute6. The minimum 
inhibitory concentration (MIC) of tigecycline was 
determined following the US Food and Drug Administration 
recommendation for Enterobacteriaceae. Endonuclease-
digested genomic DNAs were separated by pulsed-field 
gel electrophoresis using a CHEF-DR III system (Bio-Rad, 
Hercules, CA, USA). Genomic DNA was digested with 
10 U of SpeI (Fermentas, Waltham, MA, USA). Running 
conditions were 21 h at 14 °C, with an initial switching 
time of 1 s and final time of 30 s at 6 V/cm.
A polymerase chain reaction (PCR) was performed to 
evaluate resistance to SMX/TMP of the 106 samples and 
to detect the genes sul1, sul2, and dfrA1. The presence of 
mobile genetic elements with the int1 and iscr2 genes was 
also investigated. The presence of sul1, sul2, dfrA, int1, 
iscr2 genes in each strain was assessed using the primers 
described below (Table 1). 
After amplification of the genes by PCR, one of the 
products of each reaction was used to perform a new PCR 
with the oligonucleotides chosen for gene sequencing. The 
amplified gene was purified using a GFXTM PCR DNA 
and Gel Band Purification kit (GE Healthcare, Chicago, 
IL, USA) according to the manufacturer’s instructions. 
The DNA quantification was estimated by using the Low 
DNA Mass Ladder (Invitrogen, Carlsbad, CA, USA).in 2% 
agarose gel electrophoresis. 
Sequencing of three different strains were performed 
t at the human USP genome Institute, using an ABI 3730 
DNA Analyzer DNA analysis system (Applied Biosystems, 
Thermo Fisher Scientific, Waltham, MA, USA) and the 
BigDye Terminator v3.1 Cycle Sequencing Kit (NimaGem, 
Nijmegen, The Netherlands). The BioEdit software version 
7.0.9 (Nucleics Pty Ltd., Woollahra, Australia) was used to 
perform the analyses. The genetic sequence was compared 
with BLAST7. This study was approved by the Ethics 
Committee of the two hospitals.
RESULTS
We evaluated data from 106 patients with S. maltophilia 
during the study period. The mean age was 57 years 
and 58% were male. There were 24 cases (22.6%) of 
colonization and 82 cases (77.6%) of infection.
Clinical samples
A total of 106 non-repeated clinical samples of 
S. maltophilia were evaluated, as described in Table 2. 
Forty-nine were isolated from blood cultures (46.2%). 
Table 2 also shows the distribution of S. maltophilia isolates 
according to the site of infection; bloodstream infection 
was the main site (44.2%) followed by the respiratory tract 
(34.9%). The patients’ comorbidities suggest some degree 
of immunosuppression (25.3%) or chronic respiratory 
disease (37.7%) (Table 2).
The antimicrobial susceptibility profile of the strains 
is shown in Table 3. The strains displayed remarkable 
resistance to SMX/TMP 23 (21.6%), and 13.3% were 
resistant to levofloxacin. The MIC50 and MIC90 of the 
106 isolates were determined by the broth microdilution 
Table 1 - Sequence of primers to amplify int1, sul1, sul2, dfrA 
and Iscr2 genes and the corresponding molecular weight of 
the targets. 
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method (Table 2). The characteristics of the 23 SMX/TMP-
resistant samples are shown in Table 4. Most were isolated at 
Hospital das Clinicas (91.3%). Nine (39.2%) samples were 
from tracheal aspirates and 10 were from blood cultures 
(43.5%). Previous use of SMX/TMP was reported in 19 
(82.6%) of the 23 patients, and the main comorbidity was 
cancer (39.1%). Fourteen (60.8%) patients were admitted 
to the intensive care unit. The sul-1 gene was found in only 
9 of 23 strains (39.1%). The antimicrobial susceptibility of 
the 23 SMX/TMP-resistant strains are shown in Table 4. 
All of them showed resistance to other antimicrobials, and 
12 (52%) also displayed resistance to levofloxacin. PCR 
detected the sul1 gene in 14 of 106 strains (13.2%) (Table 2). 
Of these isolates, nine displayed resistance to SMX/TMP, 
with MICs ranging from 8 to 128 μg/mL.
Twenty-one strains (19.8%) carried the integrase1 (int1) 
gene, of which nine displayed resistance to SMX/TMP. The 
sul1 gene was detected in seven cases (MIC50, 8 μg/mL; 
MIC90, 128 μg/mL). On the other hand, 14 samples 
harboring int1 and negative for the sul1 gene presented lower 
SMX/TMP MICs (MIC50, 2 μg/mL; MIC90, 16 μg/mL). 
The sul2 gene was detected in only one SMX/TMP-resistant 
Table 2 - Clinical, epidemiological and microbiological description of 106 S. maltophilia isolates in two hospitals in Sao Paulo over 
a 2-year period.
Characteristics Total 106, n (%) SMX/TMT resistance, n (%)
Clinical isolates
Blood 46 (44.3) 6 (26)
Catheter tip 4 (3.8) 4 (17.4)
Tracheal aspirate/bronchoalveolar lavage 31 (29.2) 10 (43.5)
Pleural fluid 1 (0.9) 0
Urine 11 (10.3) 1 (4.3)
Bone 2 (1.8) 1 (4.3)
Others 9 (8.5) 1 (4.3)
Site of infection
Primary bloodstream infection 15 (14.1) 6 (20)
Central venous catheter infection 32 (30.1) 4 (12.5)
Respiratory tract infection 37 (34.1) 10 (27.7 )
Urinary tract infection 11 (10.3) 1 (9)
Osteomyelitis 2 (1.8) 1 (50)
Others 9 (8.5) 1 (12.5)
Resistance genes
sul1 14 (13.2) 8 (34.8)
sul2 1 (0.94) 1 (4.3)
dfrA1 1 (0.94) 0
Mobile genetic elements
Integron 21 (19.8) 9 (39.1)
Iscr2 1 (0.94) 1 (4.3)
Underlying disease
Chronic respiratory disease 40 (37.7)
Hematologic malignancy 15 (14.1)
Solid tumor 11 (10.3)
Chronic renal insufficiency 10 (9.4)
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strain (MIC, 16 μg/mL), which was sul1 negative. No SMX/
TMP susceptible strain was positive for sul2 (Table 4). Of 
all 106 strains tested, only one that was susceptible to SMX/
TMP was positive for the dfrA1 gene (MIC, 0.25 μg/mL) 
(Table 2). ISCR2 was evaluated in the SMX/TMP-resistant 
strains and was identified only in the strain harboring the 
sul2 gene.
Figure 1 shows a graphical representation of the genes 
from a S. maltophilia strain (number 24) carrying sul2 and 
iscr2 genes. It shows a sequence of 1,713 bp corresponding 
Table 3 - Minimal inhibitory concentrations (MIC50 and MIC90) by the microdilution method and antimicrobial susceptibility profile 
of 106 S. maltophilia isolates. 
Antibiotics MIC50 mg/µL MIC90 mg/µL
Antimicrobial susceptibility 
profile (%)
Sulfamethoxazole/ trimethoprim 1 32 83 (78.3%)
Levofloxacin 1 4 87 (82%)
Ceftazidime 64 ≥ 128 22 (20.7%)
Minocycline ≤ 0.25 2 105 (99%)
Ciprofloxacin 4 32 15(14.2%)
Chloramphenicol 16 64 33 (31.1%)
Ticarcillin-Acid. Clavulanate 32 128 29 (27.4%)
Tigecycline 1 2 97 (91.6%)










LVX CAZ CIP CLO TGC TIM
HC BAL + − − − 8 R R R R S R
ACC CVC + + + − 8 S R R R S R
ACC CVC + + + − >128 S R R R S R
HC Blood + − − − 8 R R R R R S
HC Bone − + − − 16 S R R R S R
HC Blood + + − − 8 S R R R S R
HC Blood − − − + 16 S R R R S R
HC TA + + − − 32 S R R S S R
HC TA + + − − 8 R R R R S R
HC TA + − − − 8 S R R R S R
HC Blood + − − − 4 R R R S S R
HC CVC + + − 32 R R R S S S
HC CVC + − − − 32 S R R R S R
HC Bile − − − − 16 R R R R S R
HC TA + + − − 16 R R R S S R
HC TA + − − − 4 S R R S S R
HC TA + − − − 16 R R R R R R
HC Blood + − + − 32 R R R R S R
HC Urine − − + − 8 R R R S S R
HC TA + − + − 4 R R R R S R
HC Blood + − + − 128 R R R R S R
HC TA + + + − 8 S R R R S S
HC TA + − + − 128 S R R S S R
SMX/TMP = Sulfamethoxazole/trimethoprim; HC = Hospital das Clinicas da FMUSP; CVC = central venous catheter; 
BAL = bronchoalveolar lavage; TA = Tracheal aspirate; LVX = levofloxacin; CAZ = ceftazidime; CIP = ciprofloxacin; 
CLO = chloramphenicol; TGC = tigecycline; TIM = ticarcillin/clavulanate.
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to the iscr2 gene, followed by a region of 184 bp representing 
the phosphoglucosamine (glmM) mutase pseudogene and 
the adjacent 730 bp sul2 gene. The integron-1 sequence 
of the sample (number 15) with MIC >128 μg/mL 
showed an approximate size of 4,000 bp containing the 
aac4 and aadA1 cassette genes and the qac/sul1 region 
(Figure 2). A schematic representation of integron class 1 in 
SMX/TMP-resistant S. maltophilia sample (number 13) 
with MIC of 8 μg/mL is shown in Figure 3. The strain 
presented in Figure 4 was sequenced (2,000 bp) and contains 
the aadA1 cassette gene and the qac/sul1 terminal region 
(SMX/TMP MIC, 8 μg/mL). Isolates were assigned the 
same pulse type if the Dice coefficient value of similarity 
was 80%8.
DISCUSSION
This study described the epidemiological profile, 
antimicrobial susceptibility, and mechanisms of resistance 
of 106 strains of S. maltophilia in two teaching, tertiary 
hospitals in Brazil. This opportunistic pathogen has 
emerged in debilitated hosts, who are often hospitalized 
for prolonged periods, using invasive devices, and are 
on broad-spectrum antibiotic therapy3. This profile was 
confirmed in our series; 63.2% of the infected patients were 
immunocompromised or had a chronic respiratory disease 
and 60.8% were admitted to the intensive care unit.
Although S. maltophilia is not a highly virulent 
pathogen9,10, it has a unique ability to colonize the 
respiratory tract and invasive devices. The main sites of 
infection in this study were CVC-related infection and lower 
respiratory tract infection as seen in many other studies9-11.
SMX/TMP is the treatment of choice for this infection, 
presenting near 90% susceptibility in most centers12,13. 
However, SMX/TMP resistance has increased in the last 
decade2,12,14. In our case series, 78.3% of the S. maltophilia 
isolates showed susceptibility to SMX/TMP. Another 
concern is that, in our study, all strains resistant to 
SMX/TMP also displayed resistance to other antimicrobials, 
such as ceftazidime (100%), ticarcicline/clavulanate (87%) 
Figure 1 - Schematic representation of the iscr2 sequence and adjacent genes from a positive sample for the S. maltophilia sul2 gene.
Figure 2 - Schematic representation of integron class 1 in an SMX/TMP-resistant S. maltophilia sample with MIC >125 µg/mL.
Figure 3 - Schematic representation of integron class 1 in an SMX/TMP-resistant S. maltophilia sample with MIC of 8 µg/mL.
Mendes et al.
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and levofloxacin (52%). On the other hand, minocycline 
and tigecycline exhibited good activity in vitro in our study. 
However, there is a lack of evidence evaluating the clinical 
efficacy of these antimicrobials to treat severe infections 
caused by S. maltophilia. Shohaib et al.15 described broad-
spectrum antimicrobial use and previous intensive care 
unit admission as risk factors for multidrug-resistant S. 
maltophilia infections. We observed that, among the patients 
with SMX/TMP-resistant strains, 82.7% had already used 
this antibiotic previously.
The sul1 gene is the main mechanism of resistance to 
SMX in S. maltophilia described to date. This gene is in the 
conserved 3’ region of class 1 integrons, which are located in 
plasmids ranging in size from 2.1 to 54.2 kB2. Another study 
described 55 genetically unrelated strains of which 25 were 
resistant to SMX/TMP, and 17 had the sul1 gene located in 
the 3’ region of the class-1 integron. The authors asserted 
that susceptible strains did not contain the sul1 gene16. In 
our series, the sul1 gene was found in 39.1% of SMX/TMP-
resistant strains and in only 6% of the 83 susceptible ones, 
suggesting an association of this gene with resistance to 
SMX/TMP. A recent study conducted in a Brazilian hospital 
reported the presence of both sul1 and sul2 in SMX/TMP-
resistant S. maltophilia16. In our study, five positive samples 
for the sul-1 gene were susceptible to SMX / TMP. Hu et al.2 
also found that 66% sensitivity to SMX/ TMP in positive 
sul-1 strains. This finding suggests that the presence of the 
gene alone does not necessarily define resistance.
The sul2 gene, which is present in transposase-like 
(ISCR) elements located in plasmids or within the bacterial 
chromosome, is also associated with resistance to SMX/
TMP6. The authors suggest that Sul2 may reduce the 
sensitivity of S. maltophilia to SMX/TMP. In this study, 
Sul2 was detected in only one of the 106 samples tested 
(0.9%), demonstrating that it is not a relevant mechanism 
in our population of patients.
Int1 genes were found in 21 samples (19.8%), and when 
associated with detection of the sul1 gene, they apparently 
resulted in strains with higher MICs.
Another mechanism of resistance recently described 
in S. maltophilia is the presence of trimethoprim- resistant 
(TMP) enzyme dehydrofolate reductase (dfrA), dfrA12, 
dfrA13, dfr17 genes located in class 1 integrons and carried 
by plasmids2. In this study, although 21 samples (19.8%) 
had the int1 gene, drfA was detectable only in one strain, 
which was sensitive to SMX/TMP (0.9%).
In our analysis, the polyclonal profile and previous use 
of SMX/TMP suggested that the resistance was related 
mainly to the antibiotic use. Moreover, some authors have 
described S. maltophilia as polyconal, highlighting the 
diversity of this microorganism10,17.
The main limitation of this study is the lack of 
information on the clinical outcome of the patients in whom 
the samples were isolated, even though the main objective 
of the study was to evaluate the characteristics of the strains. 
S. maltophilia has a wide variety of resistance mechanisms. 
Most isolates resistant to SMX/TMP did not have the 
mechanism defined in this study. Intrinsic mechanisms 
such as inducible efflux pumps have not been evaluated18,19.
CONCLUSION
In conclusion, this study showed that S. maltophilia 
infection was observed mostly in severe immunocompromised 
patients. The most frequent SMX/TMP resistance mechanism 
was the sul1 gene associated with previous use of this 
antibiotic. These findings warn on the potential spread of the 
resistance to SMX/TMP in hospital settings.
Figure 4 - Representation of the clonality profile obtained by the pulsed-field gel electrophoresis method with the SpeI enzyme, of 
17 positive strains for the S. maltophilia sul1 gene with resistance to SMX/TMP.
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